Edastuskiri

To:  National Focal Points for Viral Respiratory Diseases, Operational Contact Points (Epi, Micro, TESSy) for( Influenza, Covid-19, SARI) for ERVI-Net  
Observer National Focal Points for Viral Respiratory Diseases (Enlargement Countries)  
Contact Points for Operations (Epi, Micro, TESSy) for ( Influenza, Covid-19, SARI) for ERVI –Net (Enlargement Countries) 

Cc:  National Coordinators, National Correspondents (Enlargement Countries)   

Dear colleagues,

We have made several changes to the Integrated reporting protocol that affect the metadata for RESPISURV, SARISURV, and INFLANTIVIR.

This includes the following changes: 

• BrandLastCOVID19Dose and DrugProphylaxisRESPI coded value lists have been updated.

• Influenza AntigenicGroup and GeneticClade coded value lists have been updated.

• RSVVacProduct coded value list has been updated and expanded to include RSV monoclonal antibodies.

• The descriptions of RSV vaccination status, date of RSV vaccine, and RSV vaccine product have been revised to reflect these changes, shifting from “vaccination” to “immunisation”.

The metadata and attached reporting protocol can be found as usual on TESSy. The reporting protocol is also published on the ECDC website.

Kind regards,

ECDC and WHO Europe respiratory virus surveillance teams

Classified as ECDC NORMAL